Page last updated: 2024-11-13

cb-839

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID71577426
CHEMBL ID3639788
SCHEMBL ID14987180
MeSH IDM000600255

Synonyms (58)

Synonym
S7655
bdbm109086
us8604016, 670
CS-3393
CHEMBL3639788
1439399-58-2
SCHEMBL14987180
CB-839 ,
telaglenastat [usan]
who 10815
cb-839 [who-dd]
unii-u6cl98glp4
u6cl98glp4 ,
2-pyridineacetamide, n-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-
HY-12248
telaglenastat
AC-31603
n-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
gtpl9053
cb839
63j ,
2-(pyridin-2-yl)-n-(5-{4-[6-({[3-(trifluoromethoxy)phenyl]acetyl}amino)pyridazin-3-yl]butyl}-1,3,4-thiadiazol-2-yl)acetamide
AKOS025396175
EX-A1310
2-?pyridineacetamide, n-?[5-?[4-?[6-?[[2-?[3-?(trifluoromethoxy)?phenyl]?acetyl]?amino]?-?3-?pyridaz
n-[6-(4-{5-[2-(pyridin-2-yl)acetamido]-1,3,4-thiadiazol-2-yl}butyl)pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
AS-75090
2-(pyridin-2-yl)-n-{5-[4-(6-{2-[3-(trifluoromethoxy)phenyl]acetamido}pyridazin-3-yl)butyl]-1,3,4-thiadiazol-2-yl}acetamide
NCGC00356145-11
praapinbuwjlga-uhfffaoysa-n
cb-839(telaglenastat)
telaglenastat [who-dd]
telaglenastat [inn]
FT-0767818
DB15232
2-(pyridin-2-yl)-n-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide
mfcd28167826
Q27075751
cb 839
cb839; cb 839 pound>>telaglenastat,
BCP28287
AMY16835
SB17221
HMS3873G13
n-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide
2-pyridineacetamide, n-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-
HMS3741E19
CCG-270102
telaglenastat (usan/inn)
D11738
nsc-798057
nsc798057
A857288
n-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide;cb-839
nsc783415
nsc-783415
nsc-795998
nsc795998

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" This pre-clinical data, combined with the established safety of telaglenastat justifies further investigation for the combination in HNSCC patients."( Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
Aziz, K; Elaban, WR; Hunt, BG; Krishnan, S; Mills, GB; Palackdharry, S; Parajuli, S; Takiar, V; Waltz, SE; Wicker, CA; Wise-Draper, TM, 2021
)
0.88

Bioavailability

CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase. Has activity in Triple receptor-Negative Breast Cancer (TNBC) cell lines. Evidence of efficacy in advanced TNBC patients.

ExcerptReferenceRelevance
" CB-839 is a potent, selective, and orally bioavailable inhibitor of both splice variants of glutaminase (KGA and GAC)."( Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Bennett, MK; Chen, L; Chernov-Rogan, T; Demo, SD; Dennison, JB; Goyal, B; Gross, MI; Janes, JR; Laidig, GJ; Lewis, ER; Li, J; Mackinnon, AL; Parlati, F; Rodriguez, ML; Shwonek, PJ; Sjogren, EB; Stanton, TF; Wang, T; Yang, J; Zhao, F, 2014
)
1.57
" Inhibition of glutaminase by allosteric GLS inhibitor bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide or by novel, potent, orally bioavailable GLS inhibitor CB-839 reduced intracellular glutamate levels and inhibited growth of AML cells."( Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Baran, N; Cai, T; Chan, SM; Davis, RE; DiNardo, C; Flores, ER; Gonzalez, D; Haferlach, T; Jacamo, R; Konoplev, S; Konopleva, M; Li, W; Lodi, A; Ma, H; Majeti, R; Matre, P; Qi, Y; Samudio, I; Schimmer, AD; Su, X; Sweeney, SR; Tiziani, S; Velez, J; Wang, T, 2016
)
0.63
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
" In contrast to previous studies, treatment of autochthonous tumour-bearing animals with Telaglenastat (CB-839), an orally bioavailable GLS inhibitor, successfully inhibits undifferentiated pleomorphic sarcoma (UPS) tumour growth."( Targeting glutamine metabolism slows soft tissue sarcoma growth.
Burrows, M; Finan, JM; Gade, TPF; Gong, YY; Huangyang, P; Khare, S; Lee, P; Malik, D; Nissim, I; Perkons, N; Rhoades, S; Simon, MC; Weljie, AM, 2020
)
0.77
" CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that has activity in Triple receptor-Negative Breast Cancer (TNBC) cell lines and evidence of efficacy in advanced TNBC patients."( Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Baguley, BC; Dechaume, AL; Katt, WP; Leung, EY; Murray, PM; Singleton, DC, 2020
)
1.47
" We found that RCC cells are highly dependent on glutamine for proliferation, and this dependence strongly correlated with sensitivity to telaglenstat (CB-839), an investigational, first-in-class, selective, orally bioavailable GLS inhibitor."( The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Chen, J; Dang, R; Emberley, E; Gross, M; Huang, T; Li, W; MacKinnon, A; Pan, A; Parlati, F; Singh, D; Sotirovska, N; Steggerda, SM; Wang, T, 2021
)
0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutaminase kidney isoform, mitochondrialMus musculus (house mouse)IC50 (µMol)0.02000.02000.02000.0200AID1908383; AID1908450
Glutaminase kidney isoform, mitochondrialHomo sapiens (human)IC50 (µMol)0.20250.00200.20252.2000AID1282095; AID1305416; AID1430327; AID1513134; AID1534330; AID1540954; AID1540959; AID1562514; AID1571774; AID1678113; AID1681955; AID1772184; AID1772253; AID1866729; AID1908385
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutaminase kidney isoform, mitochondrialHomo sapiens (human)Kd0.09870.09200.09870.1060AID1540958; AID1772194; AID1908396
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
suckling behaviorGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
glutamate biosynthetic processGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
glutamine catabolic processGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
chemical synaptic transmissionGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
protein homotetramerizationGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
intracellular glutamate homeostasisGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
glutaminase activityGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
protein bindingGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
mitochondrionGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
mitochondrial matrixGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
cytosolGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
synapseGlutaminase kidney isoform, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (141)

Assay IDTitleYearJournalArticle
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1513136Aqueous solubility of the compound in pH 2.3 citrate buffer2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
AID1908402Inhibition of GLS1 in human HCT-116 cells assessed as increase in glutamine level at 100 to 300 nM incubated for 12 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1562522Protein binding in human plasma assessed as unbound fraction by LC-MS-based equilibrium dialysis analysis2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1908411Inhibition of GLS1 in human HCT-116 cells assessed as reduction in basal oxygen consumption rate at 1 uM measured after 12 hrs by seahorse XFe analyzer method2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1908409Antiproliferative activity against mouse H22 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1622880Antiproliferative activity against human MDA-MB-231met2 cells2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1908407Inhibition of GLS1 in human HCT-116 cells assessed as decrease in alpha-ketoglutarate level at 100 to 300 nM incubated for 12 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772186Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1540965Inhibition of GLS1 in human HCT116 cells assessed as reduction in intracellular glutamate levels incubated for 4 hrs by Amplex red glutamic acid assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1622889Antitumor activity against human NCI-H2122 cells harboring KRAS mutant xenografted in mouse assessed as tumor growth inhibition co-treated with selumetinib relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1540958Binding affinity to human GLS1 expressed in Escherichia coli strain BL21 (DE3)pLysS by SPR assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1540961Inhibition of human GLS1 expressed in Escherichia coli strain BL21 (DE3)pLysS pre-incubated for 10 mins before glutamine addition and measured after 60 mins by bovine liver glutamate dehydrogenase based coupled enzyme assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1908393Metabolic stability in human liver microsomes assessed as parent compound remaining at 10 uM measured after 30 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772194Binding affinity to human GLS1 expressed in Escherichia coli strain BL21 (DE3) by ITC analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1622888Antitumor activity against human NCI-H2122 cells harboring KRAS mutant xenografted in mouse assessed as tumor growth inhibition relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1772215Metabolic stability in human liver microsomes assessed as clearance at 10 uM preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1772218Half life in Sprague-Dawley rat at 5 mg/kg, iv measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1772187Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1571781Antiproliferative activity against human HCT116 cells after 5 days by EZMTT reagent-based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1908450Inhibition of GLS1 in mouse brain assessed as inhibition of glutamate production using glutamine as substrate incubated for 1 hr by coupled assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1908406Inhibition of GLS1 in human HCT-116 cells assessed as decrease in malate level at 100 to 300 nM incubated for 12 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1908396Binding affinity to human GLS1 assessed as dissociation constant by surface plasmon resonance analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772223AUC(0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1571792Metabolic stability in ICR mouse blood after 2 hrs by HPLC analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1772225Clearance in Sprague-Dawley rat at 5 mg/kg, iv measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1622884Antitumor activity against human JIMT1 cells xenografted in mouse assessed as tumor growth inhibition at 200 mg/kg, po administered BID co-treated with paclitaxel relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1571778Antiproliferative activity against mouse H22 cells after 5 days by EZMTT reagent-based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1681955Inhibition of recombinant human GLS1 using glutamine as substrate preincubated for 10 mins followed by substrate addition and measured after 20 mins by glutamate oxidase/horseradish peroxidase-coupled Amplex UltraRED reagent based fluorescence assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
AID1622881Antitumor activity against human CTG-0052 cells xenografted in mouse assessed as tumor growth inhibition at 200 mg/kg, po administered BID relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1282096Cytotoxicity against human MDA-MB-231 cells measured on 6th day by hemocytometry2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design and evaluation of novel glutaminase inhibitors.
AID1772220Cmax in Sprague-Dawley rat at 200 mg/kg, po measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1571786Antitumor activity against human HCT116 cells xenografted in nude mouse assessed reduction in tumor weight at 10 mg/kg, sc administered for 14 consecutive days2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1772231Antitumor activity against human HCT-116 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 200 mg/kg, po administered twice daily measured after 28 days2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1908383Inhibition of GLS1 in mouse kidney assessed as inhibition of glutamate production using glutamine as substrate incubated for 1 hr by coupled assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1540963Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1908413Inhibition of GLS1 in human HCT-116 cells assessed as reduction in ATP production at 1 uM measured after 12 hrs by seahorse XFe analyzer method2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1430338Cytotoxicity against human erlotinib-resistant HCC827 cells assessed as growth inhibition after 48 hrs by CCK8 assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor.
AID1571789Antitumor activity against mouse H22 cells transplanted in ICR mouse assessed as reduction in tumor weight at 10 mg/kg, sc administered once daily for 10 consecutive days relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1772185Binding affinity to human GLS1 expressed in Escherichia coli strain BL21 (DE3) assessed as change in melting temperature by SYPRO orange dye based protein thermal shift assay2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1305416Inhibition of human kidney type glutaminase (124 to 669 residues) using L-[3H]-glutamine as substrate after 45 mins by topcount method2016ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5
Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold.
AID1540959Inhibition of N-[2-[(3',6'-dihydroxy-1-oxo-spiro[isobenzofuran-3,9'-xanthene]-5-yl)carbamothioylamino]ethyl]-N'-[6-[4-[5-[[2-(2-pyridyl)acetyl]amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]pentanediamide binding to human GLS1 expressed in Escherichia 2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1772210Distribution coefficient, logD of the compound at pH 7.4 by LC-MS based shake-flask method2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1622887Antitumor activity against human RPMI8226 cells xenografted in mouse assessed as tumor growth inhibition at 200 mg/kg, po administered BID co-treated with pomalidomide relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1622882Antitumor activity against human JIMT1 cells xenografted in mouse assessed as tumor growth inhibition at 200 mg/kg, po administered BID relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1513137Aqueous solubility of the compound in pH 2.3 citrate buffer containing 20% HPBCD2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
AID1772224AUC(0 to infinity) in Sprague-Dawley rat at 200 mg/kg, po measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1772184Inhibition of recombinant human GLS1 expressed in Escherichia coli strain BL21 (DE3) preincubated for 10 mins before glutamine addition and measured after 60 mins by bovine liver glutamate dehydrogenase based coupled enzyme assay2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1571776Antiproliferative activity against human A549 cells after 5 days by EZMTT reagent-based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1908394Metabolic stability in human liver microsomes assessed as parent compound remaining at 10 uM measured after 60 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772226Clearance in Sprague-Dawley rat at 200 mg/kg, po measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1908389Metabolic stability in human plasma assessed as parent compound remaining at 1 uM measured after 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1908412Inhibition of GLS1 in human HCT-116 cells assessed as reduction in maximal oxygen consumption rate at 1 uM measured after 12 hrs by seahorse XFe analyzer method2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1622891Antitumor activity against human NCI-H1650 cells harboring EGFR mutant xenografted in mouse assessed as tumor growth inhibition co-treated with erlotinib relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1772213Metabolic stability in human plasma assessed as compound remaining after 2 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1534330Inhibition of GAC (unknown origin)2019European journal of medicinal chemistry, Feb-01, Volume: 163Discovery and development of small molecule modulators targeting glutamine metabolism.
AID1571803Drug metabolism mouse liver microsomes assessed as metabolite formation due to loss of terminal pyridine and oxygen at 50 uM by LC-MS/MS analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1681952Intrinsic clearance in rat liver microsomes assessed per kg protein at 1 uM measured up to 45 mins in presence of NADPH by LC-MS/MS analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
AID1772228Apparent volume of distribution in Sprague-Dawley rat at 200 mg/kg, po measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1571784Induction of ROS generation in human A549 cells at 10 uM after 12 hrs by DCFH-DA staining-based fluorescence microscopic analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1571794Retention time of compound in mouse liver microsomes at 50 uM by LC-MS/MS analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1772219Half life in Sprague-Dawley rat at 200 mg/kg, po measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1571782Antiproliferative activity against human HCT116 cells after 5 days by EZMTT reagent-based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1562525Volume of distribution at steady state in iv or po dosed Han Wistar rat2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1622895Inhibition of GAC (unknown origin)2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1562520Intrinsic clearance in human hepatocytes assessed per million cells2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1678111Inhibition of human recombinant glutaminase assessed as reduction in glutamate production in presence of NADPH-dependent glutamate dehydrogenase preincubated 60 mins by coupled biochemical assay2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker.
AID1562526Oral bioavailability in Han Wistar rat2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1908410Antiproliferative activity against mouse CT26 cells overexpressing GLS1 assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1908392Binding affinity to GLS1 in human HCT-116 cells assessed as increase in thermal stability upto 50 degC at 10 uM measured after 6 hrs by CETSA assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1282095Inhibition of recombinant HIs-tagged human GAC (residue 72-603 aa) expressed in Escherichia coli after 10 mins using glutamine as substrate2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design and evaluation of novel glutaminase inhibitors.
AID1540962Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1571793Metabolic stability in mouse liver microsomes at 50 uM after 4 hrs in presence of NADPH by HPLC analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1772229Oral bioavailability in Sprague-Dawley rat at 200 mg/kg measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1562519Lipophilicity, log D of the compound at pH 7.42019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1772214Metabolic stability in human liver microsomes assessed as half life at 10 uM preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1622890Antitumor activity against human NCI-H1650 cells harboring EGFR mutant xenografted in mouse assessed as tumor growth inhibition relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1540966Induction of ROS generation in human HCT116 cells incubated for 12 hrs by DCFH-DA dye based flow cytometric analysis2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1772227Apparent volume of distribution in Sprague-Dawley rat at 5 mg/kg, iv measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1908386Binding affinity to human GLS1 assessed as stabilization of protein by measuring change in melting temperature by protein thermal shift assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1678113Allosteric inhibition of human kidney glutaminase using [3H]-Glutamine as substrate in presence of inhibitor incubated for 45 mins by Perkin Elmer based assay2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker.
AID1908387Metabolic stability in human liver microsomes assessed as intrinsic clearance at 10 uM by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772232Toxicity in BALB/c nude mouse xenografted with human HCT-116 cells assessed as tolerability at 200 mg/kg, po administered twice daily measured after 28 days2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1571773Inhibition of GDH (unknown origin) using NADP+ and glutamate as substrate preincubated for 0.5 hrs followed by substrate addition and measured after 1 hr by EZMTT reagent-based UV-Vis absorbance assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1682005In vivo inhibition of GLS1 in CD-1 mouse xenografted with human H2122 cells assessed as reduction in ratio of glutamate to glutamine level at 250 mg/kg, po administered twice daily measured 8 hrs post dose on day 4 by LC-MS analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
AID1430339Cytotoxicity against human HT1080 cells assessed as growth inhibition after 48 hrs by CCK8 assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor.
AID1571788Antitumor activity against human HCT116 cells xenografted in nude mouse assessed induction of tumor necrosis at 10 mg/kg, sc administered for 14 consecutive days by hematoxylin and eosin staining-based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1622885Antitumor activity against human RPMI8226 cells xenografted in mouse assessed as tumor growth inhibition at 200 mg/kg, po administered BID relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
AID1681953Intrinsic clearance in human liver microsomes assessed per kg protein at 1 uM measured up to 45 mins in presence of NADPH by LC-MS/MS analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
AID1908404Inhibition of GLS1 in human HCT-116 cells assessed as decrease in aspartate level at 100 to 300 nM incubated for 12 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1908403Inhibition of GLS1 in human HCT-116 cells assessed as decrease in glutamate level at 100 to 300 nM incubated for 12 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772212Metabolic stability in mouse plasma assessed as compound remaining after 2 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1908405Inhibition of GLS1 in human HCT-116 cells assessed as decrease in fumarate level at 100 to 300 nM incubated for 12 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772237Cmax in BALB/c nude mouse plasma xenografted with human HCT-116 cells at 200 mg/kg, po administered twice daily for 28 days2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1681951Kinetic aqueous solubility of compound in pH 7.4 phosphate buffer at 100 uM incubated for 1 hr under shaking condition by LC-MS/MS analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
AID1430327Inhibition of recombinant KGA (unknown origin) using glutamine as substrate2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor.
AID1571800Inhibition of biotinylated BPTES binding to human KGA up to 10 uM by biomolecular interaction assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1908408Inhibition of GLS1 in human HCT-116 cells assessed as decrease in glutathione level at 100 to 300 nM incubated for 12 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1562517Antiproliferative activity against human NCI-H1703 cells assessed as reduction in cell growth after 5 days by SYTOX green staining-based assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1772238fCmax in BALB/c nude mouse plasma xenografted with human HCT-116 cells at 200 mg/kg, po administered twice daily for 28 days2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1772252Ratio of fCmax in BALB/c nude mouse plasma xenografted with human HCT-116 cells at 200 mg/kg, po administered twice daily for 28 days to IC50 for human HCT-116 cells2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1908391Antiproliferative activity against human MDA-MB-436 cells overexpressing GLS1 assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1513134Inhibition of GAC (unknown origin) assessed as NADH formation using 10 mM glutamine as substrate preincubated for 60 mins2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
AID1562514Inhibition of recombinant 6His-tagged GLS1 KGA isoform (unknown origin) (63 to 669 residues) expressed in Escherichia coli using glutamine as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by amplex red staini2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1571774Inhibition of human KGA preincubated for 15 to 30 mins followed by substrate addition and measured after 3 to 4 hrs by GDH-EZMTT reagent-based GDH coupled assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1571802Antitumor activity against mouse H22 cells transplanted in ICR mouse assessed as reduction in tumor size at 10 mg/kg, sc administered once daily for 10 consecutive days relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1772222AUC(0 to t) in Sprague-Dawley rat at 200 mg/kg, po measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1772253Inhibition of GLS1 (unknown origin)2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1571779Antiproliferative activity against human Caki1 cells after 5 days by EZMTT reagent-based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1571777Antiproliferative activity against mouse H22 cells after 5 days by EZMTT reagent-based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1562518Thermodynamic aqueous solubility of the compound at pH 7.42019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1540954Inhibition of human GLS1 assessed as reduction in glutamate production in presence of NADPH-dependent glutamate dehydrogenase by coupled biochemical assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1571780Antiproliferative activity against human Caki1 cells after 5 days by EZMTT reagent-based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1562516Inhibition of GLS in human PC3 cells using glutamine as substrate measured after 6 hrs by amplex red staining-based horseradish peroxidase/glutamate oxidase coupled assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1908439Antitumor activity against human HCT-116 cells xenografted in BALB/c SPF mouse assessed as tumor growth inhibition at 100 mg/kg, ip administered BID for 21 days2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772211Intrinsic aqueous solubility of compound at pH 7.4 by LC-MS based shake-flask method2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1540964Binding affinity to human GLS1 expressed in Escherichia coli strain BL21 (DE3)pLysS assessed as change in melting temperature by SYPRO orange dye based protein thermal shift assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1908385Allosteric inhibition of human GLS1 using glutamine as substrate incubated for 60 mins by NADH/NADPH-based absorbance analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1571785Antitumor activity against human HCT116 cells xenografted in nude mouse assessed reduction in tumor size at 10 mg/kg, sc administered for 14 consecutive days2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1908390Antiproliferative activity against human HCT-116 cells overexpressing GLS1 assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1772221AUC(0 to t) in Sprague-Dawley rat at 5 mg/kg, iv measured upto 72 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1562523Intrinsic clearance in rat hepatocytes assessed per million cells2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1772217Metabolic stability in mouse liver microsomes assessed as clearance at 10 uM preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1562524Clearance in iv or po dosed Han Wistar rat2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1772233Toxicity in BALB/c nude mouse xenografted with human HCT-116 cells assessed as body weight loss at 200 mg/kg, po administered twice daily for 28 days and measured every 3 days2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1562521Intrinsic clearance in human microsomes2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1866729Inhibition of GLS-1 (unknown origin)2022European journal of medicinal chemistry, Apr-15, Volume: 234Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification.
AID1571775Antiproliferative activity against human A549 cells after 5 days by EZMTT reagent-based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
AID1282097Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins by LC-MS/MS analysis in presence of 1 mM NADPH2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design and evaluation of novel glutaminase inhibitors.
AID1681954Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by celltiter-fluor assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
AID1772216Metabolic stability in mouse liver microsomes assessed as half life at 10 uM preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1772239Free plasma protein in mouse2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
AID1908388Metabolic stability in human liver microsomes assessed as half life at 10 uM by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
AID1540969Distribution coefficient, logD of the compound incubated for 72 hrs by LC-MS based shake-flask method2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
AID1305417Time-dependent inhibition of human kidney type glutaminase (124 to 669 residues) using L-[3H]-glutamine as substrate by topcount method2016ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5
Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's38 (53.52)24.3611
2020's33 (46.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.44 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index56.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.82%)5.53%
Reviews3 (4.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (92.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]